Squawk on the Street SOTS 2nd Hour: Nvidia in Correction Territory, Trump Takes Aim at PBMs, CNBC Fed Survey 12/17/24
Dec 17, 2024
Vamil Devan, a Guggenheim Securities analyst specializing in the pharmaceutical sector, dives into pressing market dynamics. He discusses Nvidia's alarming plunge into correction territory and its implications for investors. Devan also analyzes President-elect Trump’s critique of pharmacy benefit managers, poised to reshape drug pricing strategies. With insights on Pfizer’s future amidst market pressures and evolving healthcare innovations, the conversation highlights a cautious outlook for major health companies facing heightened scrutiny.
AI Snips
Chapters
Transcript
Episode notes
Retail Sales
- Retail sales show consumer strength, with notable gains in auto and online purchases.
- Spending was weaker in department stores, food services, and clothing.
Economic Outlook
- Lisa Shallott argues that a two-speed economy exists, with some needing rate cuts.
- She predicts a single-digit market for next year due to high valuations.
Trump on PBMs
- President-elect Trump criticizes pharmacy benefit managers (PBMs) for high drug costs.
- He plans to eliminate these "middlemen," impacting companies like CVS and Cigna.